Cannabis Report
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

That would be a very simple answer -

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BlackDoggie Member Profile
 
Followed By 9
Posts 577
Boards Moderated 0
Alias Born 02/17/17
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/22/2018 8:16:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2018 7:46:52 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/22/2018 7:45:17 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/8/2018 4:06:32 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 5/4/2018 10:54:38 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/26/2018 5:09:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/11/2018 6:09:06 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/9/2018 4:34:49 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 3/26/2018 5:27:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2018 5:25:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2018 8:02:44 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/26/2018 6:02:12 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/23/2018 4:28:34 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/23/2018 4:22:05 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 3/22/2018 7:33:32 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 3/20/2018 7:37:02 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/20/2018 7:32:32 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/20/2018 6:09:16 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/20/2018 6:09:16 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 3/14/2018 3:03:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/14/2018 7:32:05 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/9/2018 5:07:49 PM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) Edgar (US Regulatory) - 3/9/2018 4:43:58 PM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) Edgar (US Regulatory) - 3/9/2018 4:01:33 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/8/2018 6:03:09 AM
BlackDoggie   Friday, 11/10/17 08:04:25 PM
Re: Inoviorulez post# 18109
Post # of 22726 
That would be a very simple answer - if the data was available, that is. There is zero indication that any data on primary endpoints was available, since it's a double-blind trial and it had not been unblinded at that point. In fact, one of the big concessions from the FDA was that CYDY could unblind data on the first 40 and conduct interim endpoint analysis.

Plain and simple, the FDA didn't have the primary endpoint data on 10/12. Unless we're all being blatantly and openly lied to by both the company and the FDA. If you want to argue that they were suggesting that the open label portion of the trial (24 weeks in conjunction with optimized background HAART) is what the FDA was looking at, I can accept that as plausible and still disagree with you.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist